Akt inhibitors in clinical development for the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue 11, 2010, Pages 1355-1366

  Pal, Sumanta Kumar ^a   Reckamp, Karen ^a   Yu, Hua ^a   Figlin, Robert A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Akt; biomarker; GSK2141795; MK 2206; PBI 05204; perifosine; RX 0201

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; ANTINEOPLASTIC AGENT; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ERUCYLPHOSPHOCHOLINE; EVEROLIMUS; GEMCITABINE; GSK 2141795; LAPATINIB; MILTEFOSINE; MK 2206; PACLITAXEL; PBI 05204; PERIFOSINE; PLACEBO; PROTEIN KINASE B INHIBITOR; RX 0201; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 418;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; BLADDER CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERABILITY; FATIGUE; FOOT PAIN; GASTROINTESTINAL HEMORRHAGE; GOUT; HEAD AND NECK CANCER; HUMAN; HYPERURICEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LEG PAIN; LEIOMYOSARCOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VISION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 77958509195     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.520701     Document Type: Review

References (90)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
5. ClarkJI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol 2003;21:3133-40
6. National Comprehensive Cancer Network Clinical Practice Guidelines: renal cell carcinoma. Available from: http://www.nccn.org; [Last accessed 29 March 2010]
7. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71
8. Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991;201:4754-81
9. Jones PF, Jakubowicz T, Pitossi FJ, et al. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA 1991;88:4171-5
10. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254:274-7
11. Jones PF, Jakubowicz T, Hemmings BA. Molecular cloning of a second form of rac protein kinase. Cell Regul 1991;2:1001-9
12. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71
13. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999;274:9133-6
14. James SR, Downes CP, Gigg R, et al. Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem J 1996;31:709-13
15. Frech M, Andjelkovic M, Ingley E, et al. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem 1997;272:8474-81
16. Mure H, Matsuzaki K, Kitazato KT, et al. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol 2010;12:221-32
17. Al-Saad S, Donnem T, Al-Shibli K, et al. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 2009;29:4175-83
18. Boormans JL, Hermans KG, van Leenders GJ, et al. An activating mutation in AKT1 in human prostate cancer. Int J Cancer 2008;123:2725-6
19. Zhang HH, Huang J, Duvel K, et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 2009;4(7):e6189
20. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10
21. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62
22. Ruiter GA, Zerp SF, Bartelink H, et al. Anti-cancer alkyl- lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti Cancer Drugs 2003;14(2):167-73
23. Li Z, Tan F, Tong J, et al. Perifosine, as a single agent, inhibits neuroblastoma tumor cell growth in in vitro and in vivo preclinical models. AACR Meeting Abstracts; 2009. p. 3205
24. Vink SR, Schellens JHM, Beijnen JH, et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006;80:207-13
25. Hilgard P, Klenner T, Stekar J, et al. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 1997;33:442-6
26. Van Ummersen L, Binger K, Volkman J, et al. A Phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004;10:7450-6
27. Verheij M, Vink SR, Schellens JHM, et al. Phase I study of combined treatment with the oral alkyl-lysophospholipid (ALP) perifosine and radiation in patients with advanced solid tumors. Meeting Abstracts. J Clin Oncol 2004;22(14 Suppl):3064
28. NCT00398814: Phase I study of perifosine + sorafenib for patients with advanced cancers. Bethesda, MD: US National Institutes of Health, Clinical trials.gov 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00398814 [Last accessed 1 September 2010]
29. NCT01049841: perifosine with temsirolimus for recurrent pediatric solid tumors. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01049841 [Last accessed 1 September 2010]
30. Breuleux M, Klopfenstein M, Stephan C, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009;8:742-53
31. Ghobrial IM, Leleu X, Rubin N, et al. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). Meeting Abstracts. J Clin Oncol 2008;26(15 Suppl):8546
32. Richardson P, Lonial S, Jakubowiak A, et al. Multi-center Phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood (ASH Annual Meeting Abstracts) 2007;110:1164
33. Richardson P, Wolf JL, Jakubowiak A, et al. Perifosine in combination with bortezomib and dexamethasone extends progression-free survival and overall survival in relapsed/refractory multiple myeloma patients previously treated with bortezombib: updated Phase I/II trial results. Blood (ASH Annual Meeting Abstracts) 2009;114:1869
34. NCT01002248: assessment of efficacy and safety of perifosine, bortezomib and dexamethasone in multiple myeloma patients. Bethesda, MD: US National Institutes of Health, Clinical trials.gov 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT01002248 [Last accessed 1 September 2010]
35. NCT00391560: Phase II study of perifosine in patients with refractory and relapsed leukemia. Bethesda, MD: US National Institutes of Health, Clinical trials.gov 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00391560 [Last accessed 1 September 2010]
36. Vogelzang NJ, Hutson TE, Samlowski W, et al. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. Meeting Abstracts. J Clin Oncol 2009;27(15S):5034
37. Cho DC, Figlin RA, Flaherty KT, et al. A Phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). Meeting Abstracts. J Clin Oncol 2009;27(15S):5101
38. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a Phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5:433-7
39. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non Small Cell Lung Cancer. Quebec, Canada: AEterna Zentaris Press Release June 8 2009: Available from: http://www.aeternazentaris.com/en/page.php?p=60&q=316 [Last accessed 1 September 2010]
40. Vukelja S, Richards D, Campos LT, et al. Randomized Phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second-or third-line metastatic colon cancer. Meeting Abstracts. J Clin Oncol 2009;27(15S):4081
41. NCT01097018: a Phase III randomized study to assess the efficacy and safety of perifosine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials. gov/ct2/show/NCT01097018? term=NCT01097018&rank=1 [Last accessed 1 September 2010]
42. Chee KG, Lara PN, Longmate J, et al. The AKT inhibitor perifosine in biochemically recurrent, hormone-sensitive prostate cancer (HSPC): a Phase II California cancer consortium trial. Meeting Abstracts. J Clin Oncol 2005;23(16 Suppl):4642
43. Marsh RdeW, Rocha Lima CM, Levy DE, et al. A Phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2007;30:26-31
44. Ernst D, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005;23:569-75
45. Argiris A, Cohen E, Karrison T, et al. A Phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006;5:766-70
46. Hirai H, Sootome H, Nakatsuru Y, et al. An allosteric Akt inhibitor, MK-2206 enhanced anti-tumor efficacy by standard of care agents or molecular targeted drugs in vitro and in vivo. AACR Meeting Abstracts; 2009. p. 3707
47. Lu W, Defeo-Jones D, Davis LJ, et al. In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor. AACR Meeting Abstracts; 2009. p. 3714
48. Trucksis M, Friedman E, Taylor A, et al. A Phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers. AACR Meeting Abstracts; 2009. p. 3604
49. Tolcher AW, Yap TA, Fearen I, et al. A Phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). Meeting Abstracts. J Clin Oncol 2009;27(15S):3503
50. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41
51. Yap TA, Patnaik A, Fearen I, et al. First-in-class Phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. Meeting Abstracts. J Clin Oncol 2010;28(15 Suppl):3009
52. NCT00460278: study of XL418 in adults with solid tumors. Bethesda, MD: US National Institutes of Health, Clinical trials.gov 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00460278 [Last accessed 1 September 2010]
53. Gallay N, Dos Santos C, Cuzin L, et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 2009;23:1029-38
54. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30
55. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
56. Yoon H, Kim DJ, Ahn EH, et al. Antitumor activity of a novel antisense oligonucleotide against Akt1. J Cell Biochem 2009;108:832-8
57. US Patent Granted for Rexahn Pharmaceuticals Leading Cancer Candidate. Rockville, MD: Rexahn Pharmaceuticals Press Release, 6 November 2006. Available from: http://www.rexahn.com/cms/index.php/2006/11/us-patent-granted-for-rexahn- pharmaceuticals-leading-cancer-candidate-2/[Last accessed 1 September 2010]
58. Marshall J, Posey J, Hwang J, et al. A Phase I trial ofRX-0201 (AKT anti-sense) in patients with an advanced cancer. Meeting Abstracts. J Clin Oncol 2007;25(18 Suppl):3564
59. NCT01028495: a safety and efficacy study of RX-0201 plus gemcitabine in metastatic pancreatic cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/ NCT0 1028495 [Last accessed 1 September 2010]
60. Handrick R, Rubel A, Faltin H, et al. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 2006;80:199-206
61. Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents 2003;3:343-53
62. Kugler W, Erdlenbruch B, Otten K, et al. MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. Int J Oncol 2004;25:1721-7
63. NCT00460278: a phase 1 dose-escalation study of the safety and pharmacokinetics of XL418 administered orally daily to subjects with solid tumors. Available from: http://www.clinicaltrials. gov [Last accessed 7 September 2010]
64. Bidyasar S, Kurzrock R, Falchook GS, et al. A first-in-human Phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6K in advanced solid tumor patients. Meeting Abstracts. J Clin Oncol 2009;27(15S):3537
65. Rhodes N, Knick V, McConnell R, et al. GSK690693, a pan-AKT kinase inhibitor has potent anti-tumor activity and shows additive effect with lapatinib. 1 Annual Meeting. AACR Meeting Abstracts; 2007. p. 279
66. Kumar R, Rhodes N, Knick V, et al. GSK690693, a pan-AKT kinase inhibitor with potent pharmacodynamic and antitumor activity in vivo. 1 Annual Meeting. AACR Meeting Abstracts; 2007. p. 277
67. Rhodes N, Heerding DA, Duckett DR, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008;68:2366-74
68. Altomare DA, Zhang L, Deng J, et al. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res 2010;16:486-96
69. NCT00493818: open-label study to investigate the safety, tolerability, PK, and pharmacodynamics of the AKT inhibitor GSK690693. Bethesda, MD: US National Institutes of Health, Clinical trials.gov 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00493818 [Last accessed 1 September 2010]
70. LoRusso P, Hurwitz H, Chiorean E, et al. AKT inhibitor GSK690693: preliminary results from the first time in human study. 1 Annual Meeting. AACR Meeting Abstracts; 2008. p. LB-68
71. Crouthamel M-C, Kahana JA, Korenchuk S, et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009;15:217-25
72. NCT00920257: a phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas. Bethesda, MD: US National Institutes of Health, Clinical trials.gov 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00920257? term=NCT00920257&rank=1 [Last accessed 1 September 2010]
73. Holland WS, Mack PC, Tepper CG, et al. Combined mTOR and AKT inhibition in renal cell carcinoma (RCC). Meeting Abstracts. J Clin Oncol 2010;28(15 Suppl):e15041
74. Barrios C, Liu M-C, Lee S, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121:121-31
75. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
76. Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010: published online May 23 2010, doi: 10.1093/annonc/mdq2 60
77. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628-38
78. Brachmann SM, Hofmann I, Schnell C, et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009;106:22299-304
79. Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. Meeting Abstracts. J Clin Oncol 2010;28(15 Suppl):3005
80. Iglehart JK. Prioritizing comparative-effectiveness research-IOM recommendations. N Engl J Med 2009;361:325-8
81. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554 (Pubitemid 38541907)
82. Amzel LM, Huang C-H, Mandelker D, et al. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008;8:665-9
83. Sarker D, Reid AHM, Yap TA, de Bono JS. Targeting the PI3K/AKT Pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15:4799-805
84. Liu D, Hou P, Liu Z, et al. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009;69:7311-19
85. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92
86. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9
87. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-85
88. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-502
89. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7
90. Pal SK, Figlin RA. Renal cell carcinoma in 2010: many options with little comparative data. Clin Adv Hematol Oncol 2010;8:1-7